Porcine Reproductive and Respiratory Syndrome Virus

dreamstime_11845641

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is an enveloped, positive stranded RNA virus that infects pigs. Disease in a naive pig herd exposed to PRRSV can be devastating. Direct contact is the most prominent route of exposure. Clinical signs may include anorexia, fever, and lethargy. Reproductive failure is characterized by late-term abortions, increased numbers of stillborn fetuses, and/or premature, weak pigs. Infection during mid-gestation may be followed by abortions, mummified fetuses, early embryonic death, and infertility. Acute phases of disease typically last two to three months after which reproductive parameters often return to normal. However, a persistent reproductive form causes a decrease in the farrowing rate and irregular returns to estrus.

Piglets can be infected in utero, which is often associated with premature farrowing. Infected litters are weak, unthrifty, or splay-legged. Congenitally infected pigs can show signs of muscle tremors, eyelid edema, conjunctivitis and/or fever. Pigs may display respiratory dyspnea. PRRSV may persist in the respiratory tract and lymphoid tissues especially the tonsils for up to 157 days after an infection. Preweaning mortality has been reported to be as high as 80%. Prevalence of PRRSV in the United States swine herds is estimated to be 60-80%. Biological Mimetics, Inc. (BMI) is applying its Immune Dampening and Refocusing Technology to the PRRSV surface glycoproteins proteins.

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

dreamstime_1958257Our Research & Development (R&D) includes human applications such as HIV & Aids, Respiratory Agents (Influenza Virus, Rhinovirus), and Non-typeable Haemophilus Influenza (NTHI). Our veterinary applications include Foot and Mouth Disease Virus (FMDV), Infectious Pancreatic Necrosis Virus (IPNV), and Porcine Reporductive & Respiratory Syndrome Virus (PRRS). You'll find more information on these topics by going to our main Research & Development page.

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza